As of November 6, 2026, Eupraxia Pharmaceuticals Inc. is a publicly traded company (Nasdaq: EPRX). The largest holder reporting an active stake on Schedule 13D is Joseph Freedman, a director, at 9%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Beutel, Goodman & Co Ltd. (8%), Morgan C. Frank (7.7%), Robert Disbrow (7%) (Schedule 13D/A, March 16, 2026).
Is this your company?
About to sign with, pay or invest in Eupraxia Pharmaceuticals Inc.? See the free Snapshot first.
Free to see. No signup.
Is Eupraxia Pharmaceuticals Inc. a real, registered company?
- Eupraxia Pharmaceuticals Inc. files with the SEC under CIK 1581178 (its SEC filings).
- Its shares are listed under the ticker EPRX on Nasdaq (SEC company record).
- Incorporated in A1, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under EUPRAXIA PHARMACEUTICALS INC. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Morgan C. Frank (filed 2026-05-12).
Who are Eupraxia Pharmaceuticals Inc.'s owners and officers?
Eupraxia Pharmaceuticals Inc.: industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-13).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-11-08)
- : Executive Officer (Form D, 2024-11-08)
- : Executive Officer (Form D, 2024-11-08)
- : Executive Officer (Form D, 2024-11-08)
- : Executive Officer (Form D, 2024-11-08)
- : Director (Form D, 2024-11-08)
- : Director (Form D, 2024-11-08)
- : Director (Form D, 2024-11-08)
- : Director (Form D, 2024-11-08)
- : Director (Form D, 2024-11-08)
- : Director (Form D, 2024-11-08)
- : Executive Officer (Form D, 2024-11-08)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-13 | James E. Besser | 4.5% |
| Schedule 13G/A, 2026-05-12 | Morgan C. Frank | 7.7% |
| Schedule 13D/A, 2026-03-16 | Joseph S. Freedman | 9% |
| Schedule 13G/A, 2026-02-17 | Morgan C. Frank | 9.2% |
| Schedule 13G/A, 2025-11-14 | Robert Disbrow | 7% |
| Schedule 13G, 2025-11-14 | Beutel, Goodman & Co LTD. | 8% |
| Schedule 13G, 2025-11-13 | James E. Besser | 10.9% |
| Schedule 13D/A, 2025-09-26 | Joseph S. Freedman | 10.2% |
Questions about who owns Eupraxia Pharmaceuticals Inc.
Who owns Eupraxia Pharmaceuticals Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Eupraxia Pharmaceuticals Inc.: Joseph S. Freedman (9%, Schedule 13D/A, filed 2026-03-16), Beutel, Goodman & Co LTD. (8%, Schedule 13G, filed 2025-11-14), Morgan C. Frank (7.7%, Schedule 13G/A, filed 2026-05-12) and Robert Disbrow (7%, Schedule 13G/A, filed 2025-11-14).
Who are the largest shareholders of Eupraxia Pharmaceuticals Inc.?
By the share each holder's latest filing reports, the largest holders of Eupraxia Pharmaceuticals Inc. on this page are Joseph S. Freedman (9%), Beutel, Goodman & Co LTD. (8%) and Morgan C. Frank (7.7%).
When did Joseph S. Freedman buy into Eupraxia Pharmaceuticals Inc.?
The filings give report dates, not purchase dates. The earliest filing from Joseph S. Freedman on this page is the Schedule 13D/A, filed 2025-09-26, reporting 10.2%; its latest, Schedule 13D/A filed 2026-03-16, reports 9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Eupraxia Pharmaceuticals Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Eupraxia Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Eupraxia Pharmaceuticals Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
How much has Eupraxia Pharmaceuticals Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-11-08 | $1.89M | $1.89M |
| Form D, 2023-08-22 | $128K | $128K |
Keep reading
More on Eupraxia Pharmaceuticals Inc. and the records around it.
Eupraxia Pharmaceuticals Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- MANCHESTER MANAGEMENT COMPANY, LLC also filed stake reports on 2 other companies: Alpha Cognition Inc. (Sep 2026), SANUWAVE Health, Inc. (Dec 2025)
- Beutel, Goodman & Co Ltd. also filed stake reports on 4 other companies: Boyd Group Services Inc. (Nov 2026), HARLEY-DAVIDSON, INC. (Feb 2026), Docebo Inc. (Jan 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/eupraxia-pharmaceuticals